Stay updated on Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    No Change Detected
  3. Check
    19 days ago
    Change Detected
    Summary
    Update to a newer revision identifier (v3.2.0) replaces the older v3.0.2.
    Difference
    0.0%
    Check dated 2025-10-01T05:55:53.000Z thumbnail image
  4. Check
    20 days ago
    Change Detected
    Summary
    Update: version revision changed from v3.0.2 to v3.1.0.
    Difference
    0.0%
    Check dated 2025-09-30T03:48:29.000Z thumbnail image
  5. Check
    27 days ago
    Change Detected
    Summary
    Removed content on Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, and Substandard Drugs, narrowing the page’s coverage of medical/pharmaceutical topics.
    Difference
    0.2%
    Check dated 2025-09-22T23:45:53.000Z thumbnail image
  6. Check
    34 days ago
    Change Detected
    Summary
    Localization update: place names now use the Tatar-language form ‘Respublika’ (e.g., Kazan’, Tatarstan, Respublika, Russia, 420029) instead of ‘Tatarstan Republic’; page revision bumped to v3.0.2, with a minor removal of the Back to Top element.
    Difference
    0.2%
    Check dated 2025-09-15T19:30:31.000Z thumbnail image
  7. Check
    42 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.
    Difference
    0.1%
    Check dated 2025-09-08T15:05:13.000Z thumbnail image
  8. Check
    49 days ago
    Change Detected
    Summary
    The webpage has undergone significant updates, including the addition of numerous facility names and locations across various countries, particularly in Europe, Asia, and Latin America. Additionally, new content related to drug safety and specific drugs has been introduced.
    Difference
    16%
    Check dated 2025-09-01T09:30:57.000Z thumbnail image

Stay in the know with updates to Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page.